Influenza vaccine: how long protection lasts
Most people can expect meaningful protection for about 4–6 months after vaccination, with effectiveness highest in the first 2–3 months and gradually waning thereafter. 1, 2
What guidelines say (frames practice and outcomes):
- ACIP recommends annual vaccination for all ≥6 months because protection wanes within the season and strains change; delaying too long risks missed vaccination and higher morbidity/mortality when influenza circulates 3, 1.
- Observed waning: VE commonly declines month-to-month within a season; faster waning seen for A(H3N2), especially in older adults, supporting timing the shot before local circulation but still early enough to ensure coverage 1.
Highest-quality recent data (adults 18–65 years; effectiveness and serology):
- Meta-analysis: protection and antibody titres persist 5–7 months, but VE against A(H3N2) and B declines markedly beyond 5 months; H1N1 protection more sustained past 5 months; titres are not sustained at 11–13 months, justifying annual dosing 2.
- Hospital data 2024/25: VE against hospitalisation for influenza A highest at 2–8 weeks, modest decline by ≥16 weeks, while B remains higher through the season—consistent with 4–6 months of useful protection against severe outcomes (morbidity/mortality) 4.
Practical, outcome-focused timing guidance:
- Aim to vaccinate so peak protection (first 2–3 months) covers the expected peak of local influenza; but do not delay if it risks missing vaccination, since any vaccination before circulation reduces hospitalisation and death 1.
- Older adults (≥65) experience faster waning—consider high-dose/adjuvanted products per ACIP season guidance, but the duration pattern (about 4–6 months of strongest benefit) still applies 1.
Pitfalls/caveats:
- Protection varies by strain and age; A(H3N2) wanes fastest, older adults wane more—plan timing accordingly 1, 2.
- Immunity does not reliably last to the next season; protection at 11–13 months is not sustained—hence yearly vaccination is essential for morbidity/mortality reduction 2.
- Even late-season vaccination is beneficial if influenza is still circulating, to reduce hospitalisation risk 1.